 NEW HAVEN, Conn., Aug. 9, 2021 PRNewswire -- Trevi Therapeutics, Inc. Nasdaq: TRVI, a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy HaduvioTM nalbuphine ER to treat serious neurologically mediated conditions, today announced the appointment of Lisa Delfini, CPA, as Chief Financial Officer and Danine Summers, as Vice President, Medical Affairs. 